Induced Pluripotent Stem Cells Market Size, Share, Trends, Growth Outlook

Induced Pluripotent Stem Cells Market is estimated to increase at a growth rate of 9.8% CAGR over the forecast period from 2024 to 2030.

The Induced Pluripotent Stem Cells Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others), By Application (Drug Development, Tissue Engineering & Regenerative Medicine, Toxicology Research, Disease Modeling), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others).

An Introduction to Induced Pluripotent Stem Cells Market in 2024

The Induced Pluripotent Stem Cells (iPSCs) market in 2024 is witnessing rapid growth driven by the increasing demand for regenerative medicine, cell-based therapies, and disease modeling applications, as well as advancements in cellular reprogramming techniques, genome editing technologies, and tissue engineering strategies. iPSCs are adult cells that have been genetically reprogrammed to exhibit pluripotency, enabling them to differentiate into various cell types found in the body, such as neurons, cardiomyocytes, and hepatocytes, for use in research, drug discovery, and therapeutic development. The market offers a variety of iPSC products and services, including cell lines, differentiation kits, and custom cell manufacturing services, tailored to meet the diverse needs of academic researchers, pharmaceutical companies, and biotechnology firms engaged in stem cell research and regenerative medicine applications. With factors such as increasing investment in regenerative medicine, growing collaborations between academia and industry, and expanding applications of iPSC technology driving demand for scalable and standardized cell production platforms, stem cell companies and research institutions are investing in automated culture systems, bioreactor technologies, and quality control measures to streamline iPSC manufacturing, improve cell quality, and accelerate clinical translation of cell-based therapies. Moreover, with a focus on personalized medicine, disease modeling, and precision oncology, the market is witnessing efforts to develop iPSC-derived cell models for studying genetic diseases, screening drug candidates, and optimizing patient-specific treatment approaches to improve therapeutic efficacy and reduce adverse effects. As the field of iPSC research and regenerative medicine continues to advance, the iPSCs market is poised for further expansion and diversification, offering versatile and transformative solutions to address the unmet medical needs of patients and revolutionize the future of healthcare.

Induced Pluripotent Stem Cells Market Trend: Advancements in Genome Editing Technologies Driving Research and Development

A significant trend in the Induced Pluripotent Stem Cells (iPSCs) market is the rapid advancements in genome editing technologies, such as CRISPR-Cas9, driving research and development activities. These technologies enable precise manipulation of iPSCs' genetic material, allowing scientists to create disease models, study genetic disorders, and develop potential therapies with greater accuracy and efficiency. As genome editing techniques continue to evolve, they offer new possibilities for generating iPSC-based models for drug screening, regenerative medicine, and personalized treatments, shaping the landscape of iPSC research and applications.

Market Driver: Increasing Investment in Regenerative Medicine and Cell Therapy Research

A key driver of growth in the Induced Pluripotent Stem Cells market is the increasing investment in regenerative medicine and cell therapy research. With a growing focus on developing innovative treatments for various diseases and conditions, there is heightened interest in utilizing iPSCs as a versatile cell source for cell-based therapies and tissue engineering applications. Government initiatives, academic collaborations, and investments from biotechnology and pharmaceutical companies are fueling research efforts aimed at harnessing the therapeutic potential of iPSCs, driving market expansion and the translation of iPSC-based technologies into clinical practice.

Induced Pluripotent Stem Cells Market Opportunity: Development of Scalable and Cost-Effective iPSC Manufacturing Technologies

An opportunity for the Induced Pluripotent Stem Cells market lies in the development of scalable and cost-effective iPSC manufacturing technologies. Current methods for iPSC generation and expansion often involve complex and labor-intensive processes, limiting scalability and increasing production costs. By investing in research and innovation, companies can explore novel approaches, such as automated culture systems, bioreactor-based production platforms, and synthetic culture matrices, to streamline iPSC manufacturing and improve efficiency. Developing scalable and cost-effective manufacturing technologies can lower barriers to entry, facilitate large-scale production of high-quality iPSCs, and enable broader adoption of iPSC-based therapies and applications in clinical settings.

Induced Pluripotent Stem Cells Market Segmentation

By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Induced Pluripotent Stem Cells Market Companies

Astellas Pharma Inc
Axol Bioscience Ltd
Cellular Engineering Technologies Inc
Cynata Therapeutics Ltd
Evotec SE
Fate Therapeutics Inc
FUJIFILM Cellular Dynamics Inc
REPROCELL Inc
STEMCELL Technologies Inc
Takara Bio Inc

 

 

Reasons to Buy the Induced Pluripotent Stem Cells Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Induced Pluripotent Stem Cells Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Induced Pluripotent Stem Cells Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Induced Pluripotent Stem Cells Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Induced Pluripotent Stem Cells Market Size Outlook, $ Million, 2021 to 2030
3.2 Induced Pluripotent Stem Cells Market Outlook by Type, $ Million, 2021 to 2030
3.3 Induced Pluripotent Stem Cells Market Outlook by Product, $ Million, 2021 to 2030
3.4 Induced Pluripotent Stem Cells Market Outlook by Application, $ Million, 2021 to 2030
3.5 Induced Pluripotent Stem Cells Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Induced Pluripotent Stem Cells Market Industry
4.2 Key Market Trends in Induced Pluripotent Stem Cells Market Industry
4.3 Potential Opportunities in Induced Pluripotent Stem Cells Market Industry
4.4 Key Challenges in Induced Pluripotent Stem Cells Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Induced Pluripotent Stem Cells Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Induced Pluripotent Stem Cells Market Outlook By Segments
7.1 Induced Pluripotent Stem Cells Market Outlook by Segments
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

8 North America Induced Pluripotent Stem Cells Market Analysis And Outlook To 2030
8.1 Introduction to North America Induced Pluripotent Stem Cells Markets in 2024
8.2 North America Induced Pluripotent Stem Cells Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Induced Pluripotent Stem Cells Market size Outlook by Segments, 2021-2030
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

9 Europe Induced Pluripotent Stem Cells Market Analysis And Outlook To 2030
9.1 Introduction to Europe Induced Pluripotent Stem Cells Markets in 2024
9.2 Europe Induced Pluripotent Stem Cells Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Induced Pluripotent Stem Cells Market Size Outlook By Segments, 2021-2030
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

10 Asia Pacific Induced Pluripotent Stem Cells Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Induced Pluripotent Stem Cells Markets in 2024
10.2 Asia Pacific Induced Pluripotent Stem Cells Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Induced Pluripotent Stem Cells Market size Outlook by Segments, 2021-2030
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

11 South America Induced Pluripotent Stem Cells Market Analysis And Outlook To 2030
11.1 Introduction to South America Induced Pluripotent Stem Cells Markets in 2024
11.2 South America Induced Pluripotent Stem Cells Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Induced Pluripotent Stem Cells Market size Outlook by Segments, 2021-2030
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

12 Middle East And Africa Induced Pluripotent Stem Cells Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Induced Pluripotent Stem Cells Markets in 2024
12.2 Middle East and Africa Induced Pluripotent Stem Cells Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Induced Pluripotent Stem Cells Market size Outlook by Segments, 2021-2030
By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Astellas Pharma Inc
Axol Bioscience Ltd
Cellular Engineering Technologies Inc
Cynata Therapeutics Ltd
Evotec SE
Fate Therapeutics Inc
FUJIFILM Cellular Dynamics Inc
REPROCELL Inc
STEMCELL Technologies Inc
Takara Bio Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others
By Application
Drug Development
Tissue Engineering & Regenerative Medicine
-Neurology
-Orthopedics
-Oncology
-Cardiovascular and Myocardial Infraction
- Diabetes
- Others
Toxicology Research
Disease Modeling
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others